Scandion Oncology is advancing a pipeline of novel therapies for the treatment of chemotherapy resistance.
Our lead candidate SCO-101 has successfully passed 4 Phase I trials and is now ready for Phase II trials.
Our second candidate, SCO-201, is at a late pre-clinical stage. We have more than 800 analogues in the pre-clinical screening phase.